New pill aims to tame dangerous immune storms from cancer therapy
Disease control
Recruiting now
This study tests a drug called CTO1681 in 54 adults with diffuse large B-cell lymphoma who are about to receive CAR-T therapy. The drug is taken three times daily for 15 days to prevent or reduce cytokine release syndrome, a potentially severe immune reaction. Researchers will mo…
Phase: PHASE1, PHASE2 • Sponsor: CytoAgents, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC